<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822415</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO-CU-2014-06-09</org_study_id>
    <nct_id>NCT04822415</nct_id>
  </id_info>
  <brief_title>Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis</brief_title>
  <official_title>Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine for Inferior Alveolar Nerve Blocks in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL&#xD;
      2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine&#xD;
      hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block&#xD;
      for patients with symptomatic irreversible pulpitis in mandibular molars.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL&#xD;
      2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine&#xD;
      hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block&#xD;
      for patients with symptomatic irreversible pulpitis in mandibular molars. Patients were&#xD;
      clinically and radiographically examined and their eligibility assessed and preoperative pain&#xD;
      was measured using the numerical rating scale (NRS). Patients were randomly assigned to one&#xD;
      of 2 groups: experimental group (2% mepivacaine) and the control group (4% articaine). After&#xD;
      15 minutes of the inferior alveolar nerve block (IANB), patients reporting lip numbness had&#xD;
      their molars accessed. No-to-mild pain response was considered success during root canal&#xD;
      preparation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anaesthetic success</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Success of mandibular inferior alveolar nerve block anesthesia during access cavity preparation and instrumentation measured using the 11-point numerical rating scale (NRS) so that no-or-mild pain is considered as anesthetic success and moderate-to-severe pain is considered anesthetic failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Supplemental anaesthesia</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The need for supplemental anaesthesia to complete treatment (Yes/No).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Symptomatic Irreversible Pulpitis</condition>
  <arm_group>
    <arm_group_label>Mepivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Articaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepivacaine</intervention_name>
    <description>IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.</description>
    <arm_group_label>Mepivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Articaine</intervention_name>
    <description>IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.</description>
    <arm_group_label>Articaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients in good health (American Society of Anesthesiologists Class I or II).&#xD;
&#xD;
          -  Patients having symptomatic irreversible pulpitis in one of their mandibular molars.&#xD;
&#xD;
          -  Age range between 18 to 50 years.&#xD;
&#xD;
          -  Patients who can understand Numerical Rating Scale (NRS).&#xD;
&#xD;
          -  Positive patient acceptance and the ability to sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant females.&#xD;
&#xD;
          -  Patients allergic to articaine, mepivacaine and/or any used medication or material.&#xD;
&#xD;
          -  Patients having active sites of pathosis in the area of injection.&#xD;
&#xD;
          -  Patients having active pain in more than one molar.&#xD;
&#xD;
          -  Patients who had taken analgesics in the 12 hours preceding treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randa ElBoghdadi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <reference>
    <citation>Allegretti CE, Sampaio RM, Horliana AC, Armonia PL, Rocha RG, Tortamano IP. Anesthetic Efficacy in Irreversible Pulpitis: A Randomized Clinical Trial. Braz Dent J. 2016 Jul-Aug;27(4):381-6. doi: 10.1590/0103-6440201600663.</citation>
    <PMID>27652697</PMID>
  </reference>
  <reference>
    <citation>Nagendrababu V, Pulikkotil SJ, Suresh A, Veettil SK, Bhatia S, Setzer FC. Efficacy of local anaesthetic solutions on the success of inferior alveolar nerve block in patients with irreversible pulpitis: a systematic review and network meta-analysis of randomized clinical trials. Int Endod J. 2019 Jun;52(6):779-789. doi: 10.1111/iej.13072. Epub 2019 Feb 12.</citation>
    <PMID>30638269</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Suzan AW Amin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mepivacaine</mesh_term>
    <mesh_term>Carticaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

